INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2016

Endoscopic bariatric therapies provide minimally invasive treatment options for obesity and related metabolic comorbidities.

This review evaluates current and emerging endoscopic bariatric therapies for obesity and associated cardio-metabolic comorbidities. Currently, two intragastric balloons have FDA approval for 6-month implantation in patients with a BMI of 30-40 kg/m². Additionally, full-thickness suturing has enabled primary endoscopic sleeve gastroplasty and Roux-en-Y gastric bypass revision as viable alternatives to surgery.

Study type
Narrative review
Who was studied
Patients with obesity (e.g., BMI range of 30-40 kg/m²)
What was measured
Efficacy, procedural technique, and evidence for endoscopic bariatric therapies

THE PAPER

Endoscopic Bariatric Therapies.

Goyal D, Watson RR. Curr Gastroenterol Rep, 2016.

PubMed 27098813 ↗DOI 10.1007/s11894-016-0501-5 ↗

Diabetes & blood sugarWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.